Single centre experience of efficacy and toxicity of reduced-dose melphalan conditioning (140 mg/m2 or 110 mg/m2) in autologous stem cell transplantation for multiple myeloma

被引：0
|
作者：
Troy-Barnes, E. [1 ]
Melotti, D. [1 ]
Camilleri, M. [1 ]
Horder, J. [1 ]
Newrick, F. [1 ]
Marfil, J. [1 ]
Lee, L. [2 ]
Mahmood, A. S.
Wisniowski, B.
Papanikolaou, X. [1 ]
Wechalekar, A. [3 ]
Sive, J. [1 ]
Popat, R. [4 ]
Yong, K. [2 ]
Rabin, N. [1 ]
Kyriakou, C. [1 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, London, England
[2] UCL, Inst Canc, London, England
[3] UCL, Ctr Amyloidosis & Acute Phase Prot, London, England
[4] Univ Coll London Hosp, Clin Res Facil, Natl Inst Hlth Res, London, England
来源：
BONE MARROW TRANSPLANTATION | 2022年 / 57卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P146
引用
收藏
页码：178 / 179
页数：2
相关论文
共 50 条
  • [21] Dose-intensive melphalan regimens (100 mg/m2 versus 200 mg/m2) in multiple myeloma patients.
    Boccadoro, M
    Bringhen, S
    Cavallo, F
    Falco, P
    Bertola, A
    Barbui, A
    Caravita, T
    Musto, P
    Pescosta, N
    Vignetti, M
    Palumbo, A
    BLOOD, 2002, 100 (11) : 431A - 431A
  • [22] Melphalan 200 mg/m2 versus 100 mg/m2 in newly diagnosed myeloma
    Palumbo, A.
    Bringhen, S.
    Petrucci, M. T.
    Falcone, A.
    Liberati, A. M.
    Lauta, V. M.
    Montanaro, M.
    Cangialosi, C.
    Morandi, S.
    D'Agostino, F.
    Cavallo, F.
    Omede, P.
    Musto, P.
    Foue, R.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 189 - 189
  • [23] Use of melphalan 280 MG/M2 plus amifostine cytoprotection and autologous stem cell transplantation in multiple myeloma patients.
    Reece, DE
    Filicko, J
    Flomenberg, N
    Howard, DS
    Meisenberg, B
    Plummer, B
    Vesole, D
    Xun, CQ
    Phillips, GL
    BLOOD, 2001, 98 (11) : 196A - 196A
  • [24] COMPARISON OF BUSULFAN plus MELPHALAN TO MELPHALAN 200 MG/M2 AS PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA
    Ahmed, S.
    Dinh, Y.
    Rondon, G.
    Andersson, B.
    Jones, R.
    Bashir, Q.
    Shah, N.
    Popat, U.
    Champlin, R. E.
    Qazilbash, M. H.
    Kebriaei, P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S251 - S251
  • [25] 200mg/m2 intravenous melphalan with autologous peripheral blood stem cell transplantation for relapsed multiple myeloma (MM).
    Huang, QA
    Sun, CJ
    Yang, TX
    Wang, WS
    BLOOD, 2002, 100 (11) : 470B - 470B
  • [26] Results of a phase I/II trial adding carmustine (300mg/m2) to melphalan (200mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
    Comenzo, RL
    Hassoun, H
    Kewalramani, T
    Klimek, V
    Dhodapkar, M
    Reich, L
    Teruya-Feldstein, J
    Fleisher, M
    Filippa, D
    Nimer, SD
    LEUKEMIA, 2006, 20 (02) : 345 - 349
  • [27] Reduced-Dose Melphalan (140 or 100 mg/m2) Maintains Efficacy and Tolerability for Multiple Myeloma Patients with Advanced Age or Renal Impairment Undergoing Auto-HCT
    Ngo, Phuong T.
    Reynolds, Samuel B.
    Nguyen, Quang L.
    Jayswal, Rani
    Weiss, Heidi L.
    Krem, Maxwell M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [28] 200 mg/m2 melphalan—the gold standard for multiple myeloma
    Sergio Giralt
    Nature Reviews Clinical Oncology, 2010, 7 : 490 - 491
  • [29] Melphalan 140mg/m2 demonstrates identical clinical outcomes to melphalan 200mg/m2 amongst patients undergoing autologous transplant for multiple myeloma: a multicentre UK study
    Sangha, J.
    Cook, G.
    Rampotas, A.
    Ward, J.
    Cavenagh, J.
    Cook, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S72 - S73
  • [30] High-dose chemotherapy and autologous peripheral stem cell transplantation in multiple myeloma - melphalan 225mg/m2 is feasible in tandem setting
    Ruckser, R
    Vedovelli, H
    Buxhofer, V
    Kitzweger, E
    Kier, P
    Tatzreiter, G
    Zelenka, P
    Hinterberger, W
    BONE MARROW TRANSPLANTATION, 2003, 31 : S86 - S86
12345